Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
Transcript
Can you provide a sneak peek of some of your key talking points at Asembia?
I'll be talking about things that we've been doing and value-based cancer care, and certainly that covers a fairly broad expanse. We've been involved with a number of our oncology clinical partners at Horizon Blue Cross Blue Shield of New Jersey, with shared savings and moving into shared risk. We worked in non–small cell lung cancer, breast cancer, prostate, non-Hodgkin’s lymphoma, colorectal, among others. And so that's what I'll be highlighting.
We also had an oncology medical home model, which was partly benchmarked from Dr. [Barbara] McAneny’s work and Dr. [John] Sprandio’s work and had some elements of the OCM [Oncology Care Model]—we did not formally participate in the OCM, and we’re, as a company, in the very early stages and some of the preliminary discussions around Capitol Hill on the OCM. But we elected to go our own way with our own value payment models and oncology medical home.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen